ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine dihydrochloride]: Discriminative stimulus properties and electrophysiological actions

Drug Development Research

Volumn 40, Issue 3, 1997, Pages 259-266

  Brioni, Jorge D ^a   Kim, David J B ^a   O'Neill, Alyssa ^a   Brodie, Mark S ^b   Decker, Michael W ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ABT 089; Drug discrimination; Ventral tegmental area

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; A 94224.3; MECAMYLAMINE; NEUROPROTECTIVE AGENT; NICOTINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOPAMINE RELEASE; DOSE RESPONSE; ELECTROPHYSIOLOGY; ENANTIOMER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REINFORCEMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TRAINING; VENTRAL TEGMENTUM;

EID: 0030762724     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199703)40:3<259::AID-DDR6>3.0.CO;2-J     Document Type: Article

References (32)

1. Arnerie SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes M, Cadman ED, Adams P, Garvey DS, Wasicak J, Williams M (1994): ABT-418: A novel cholinergic ligand with cognition enhancing and anxiolytic activities: I. In vitro characterization. J Pharmacol Exp Ther 270:310-318.
2. Arneric SP, Campbell J, Holladay M, Johnson P, Lin N, Marsh K, Peterson B, Hi Y, Ouigley S, Roberts E, Rodriguez D, Sullivan JP, Trivedi J, Williams M (1997): ABT-089 [3-(2(S)-pyrrolininylmethoxy)-2-methyl-pyridine]: An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Dev Res, submitted.
3. Brioni JD, Kim DJB, O'Neill AB, Williams JEG, Decker MW (1994): Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res 643:1-9.
4. Brioni JD, Kim DJB, Brodie MS, Decker MW, Arneric SP (1995): ABT-418: Discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology 107:368-375.
5. Brioni JD, Kim DJB, O'N'eill AB (1996a): Nicotine cue: Lack of effect of the α7 nicotinic antagonist methyllycaconitine. Eur J Pharmacol 301:1-5.
6. Brioni JD, Decker MW, Sullivan JR Arneric SP (1996b): The pharmacology of (-)-nicotine and novel cholinergic channel activators. Adv Pharmacol 37:153-214.
7. Brodie MS (1991): Low concentrations of nicotine increase the firing rate of neurons of the ventral tegmental area "in vitro." In Adlkofer F, Thurau K (eds): Advances in Pharmacological Sciences: Effects of Nicotine on Biological Systems. Basel/Boston: Birkhauser Verlag: pp 373-377.
8. Brodie MS, Shefner SA, Dunwiddle TV (1990): Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 508:65-69.
9. Calabresi P, Lacey MG, North RA (1989): Nicotinic excitation of rat ventral tegmental neurons in vitro studied by intracellular recording. Br J Pharmacol 98:135-140.
10. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raskiewickz JL, Kang CH, Kim DJB, Ciardina WJ, Williams M, Arneric SP (1994): ABT 418: A novel cholinergic ligand with cognition enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 270:319-328.
11. Decker MW, Brioni JD, Bannon AW, Arneric SP (1995): Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics. Life Sci 56:545-570.
12. Decker MW, Bannon AW, Curzon P, Gunther K, Brioni JD, Holladay M, Lin N, Li Y, Daanen J, Buccafusco J, Prendergast M, Jackson W, Arneric SP (1997): ABT-089 [2-methyl-3-(2-(s)-pyrrolidinylmethoxy) pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther, submitted.
13. DiChiara G, Imperato A (1988): Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic dopamine system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
14. Fuxe K, Andersson K, Harfstrand A, Eneroth P, Mora MPdl, Agnati LF (1990): Effects of nicotine on synaptic transmission in the brain. In Wonnacott S, Russell MAH, Stolerman IP (eds): Nicotinic Psychopharmacology: Molecular, Cellular and Behavioural Aspects. Oxford: Oxford University Press, pp 194-225.
15. Grace AA, Bunney BS (1983): Intracellular and extracellular electrophysiology of nigral dopaminergic neurons 1. Identification and characterization. Neuroscience 10:301-315.
16. Hirschhorn I, Rosecrans J (1974): Studies on the time course and the effect of cholinergic and adrenergic receptor blockers on the stimulus effect of nicotine. Psychopharmacologia 40:109-120.
17. Imperato A, Mulas A, DiChiara C (1986): Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337-338.
18. Kim DJB, Brioni JD (1995): Modulation of the discriminative stimulus properties of (-)-nicotine by ethanol and diazepam. Drug Dev Res 4 34:47-54.
19. Laccy MG, Mercury NB, North RA (1989): Two cells types in rat snbstantia nigra zona compacta distinguished by membrane properties and actions of dopamine and opioids. J Neurosci 9:1233-1241.
20. Lin N, Gunn D, Ryther K, Garvey D, Donnelly-Roberts D, Decker MW, Brioni JD, Buckley M, Rodrignez A, Marsh K, Aiiderson D, Sullivan JP Williams M, Arneric SD, Holladay M (1997): Structure-activity studies on ABT-089: An orally bioavailable 3-pyridil ether cholinergic channel modulator with cognitive enhancing proper-ties. J Med Chem 40:385-390.
21. Meltzer L, Rosecrans J, Aceto M, Hams L (1980): Discriminative stimulus properties of the optical isomers of nicotine. Psychopharmacology 68:283-286.
22. Mueller AL, Brodie MS (1989): Intracellular recording from putative dopamine containing neurons in the ventral tegmental area of Tsai in a brain slice preparation. J Neurosci Methods 28:16-22.
23. Reavill C, Stolerman IP (1987): Interaction of nicotine with dopaminergic mechanisms assessed through drug discrimination and rotational behaviour in rats. J Psychopharmacol 1:264-273.
24. Reavill C, Walther B, Stolerman I, Testa B (1990): Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29:619-624.
25. Rosecrans JA, Chance WT (1977): Cholinergic and non-cholinergic aspects of the discriminative stimulus properties of nicotine. In Lal H (eds): Discriminative Stimulus Properties of Drugs. New York: Plenum, pp 155-185.
26. Schechter M, Rosecrans J (1972): Nicotine as a discriminative cue in rats: Inability of related drugs to produce the nicotine-like cueing effect. Psychopharmacologia 27:379-387.
27. Spencer DG, Emmett-Oglesby MW (1985): Parallel processing strategies in the application of microcomputers to the behavioral laboratory. Behav Res Methods Instrument 17:294-300.
28. Stolerman IP, Pratt JA, Garcha HS, Giardini V, Kumar R (1983): Nicotine cue in rats analyzed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms. Neuropharmacology 22:1029-1037.
29. Stolerman I, Garcha H, Pratt J, Kumar R (1984): Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology 84:413-419.
30. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson D, Gopalakrishnan M, Xue I, Piattoni-Kaplan M, Molinari E, Campbell J, McKenna D, Gunn D, Lin N, Ryther K, He Y, Holladay M, Wonnacott S, Williams M, Arneric SP (1997): ABT-089 [2-methvl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther, submitted.
31. Wise RA (1987): The role of reward pathways in the development of drug dependence. Pharmacol Ther 35:227-263.
32. Wise R, Bozarth M (1985): Brain mechanisms of drug reward and euphoria. Psychiatr Mod 3:445-460.